Opinion

Video

How JAK Inhibitors Have Shaped the Landscape of MF

Author(s):

Andrew Kuykendall, MDRaajit K. Rampal, MD, PhD

Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, discuss how JAK inhibitors have reduced spleen size (splenomegaly) and constitutional symptoms like fatigue and fever in patients with myelofibrosis but that there is still room for improvement in treating other aspects of the disease like anemia and bone marrow fibrosis. They also share insights about the potential for combination therapies that target multiple pathways.

Related Videos
Sattva S. Neelapu, MD
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
John Burke, MD
Justin M. Watts, MD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Mikkael A. Sekeres, MD, professor, medicine, chief, Division of Hematology, Leukemia Section, the University of Miami Sylvester Comprehensive Cancer Center
Ashwin Kishtagari, MD
Ben Levy, MD, and Yan Leyfman, MD
Related Content
Kathleen A. Dorritie, MD, of University of Pittsburgh Medical Center Hillman Cancer Center​
June 11th 2024

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Angelos Stergiou, MD, ScD hc
June 10th 2024

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Anthony M. Hunter, MD
June 9th 2024

Factors for JAK Inhibitor Selection in Myelofibrosis in the First Line and Beyond

The FDA has approved imetelstat (Rytelo) for adults with low- to intermediate-1–risk myelodysplastic syndrome (MDS) and transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are not eligible for erythropoiesis-stimulating agents.
June 7th 2024

FDA Approves Imetelstat for Low- to Intermediate-1–Risk MDS With Transfusion-Dependent Anemia